These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 7536864

  • 21. Long-term culture of autologous bone marrow for marrow reconstitution following high-dose chemotherapy. Purging with tumor surface antigen directed human-human monoclonal antibody.
    Alonso K, Medenica R, Morehead G.
    Prog Clin Biol Res; 1994; 389():111-8. PubMed ID: 7700892
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Autologous bone marrow transplantation for leukemia.
    Stuart RK.
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):40-54. PubMed ID: 8211215
    [Abstract] [Full Text] [Related]

  • 24. [An experimental study on bone marrow purging in vitro for patients with chronic myelogenous leukemia].
    Liu J, Jiang J, Zhang Y, Wu D, Yang G, Huang X, Wei X.
    Hua Xi Yi Ke Da Xue Xue Bao; 2001 Dec; 32(4):599-601. PubMed ID: 12528561
    [Abstract] [Full Text] [Related]

  • 25. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.
    Veena P, Cornetta K, Davidson A, Agüero B, McMahel J, Traycoff CM, Srour EF.
    Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Antisense oligonucleotide OL (1) p53 for in vitro purging of autologous bone marrow in acute myelogenous leukemia.
    Bishop MR, Warkentin PI, Jackson JD, Bayever E, Iversen PL, Whalen VI, Lastovica J, Haines K, Kessinger A.
    Prog Clin Biol Res; 1994 Jun; 389():183-7. PubMed ID: 7700901
    [No Abstract] [Full Text] [Related]

  • 28. Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide.
    Skorski T, Nieborowska-Skorska M, Barletta C, Malaguarnera L, Szcyzlik C, Chen ST, Lange B, Calabretta B.
    J Clin Invest; 1993 Jul; 92(1):194-202. PubMed ID: 8325984
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C, Regazzi E, Andrizzi C, Savoldo B, Garau D, Montefusco E, Vignetti M, Mandelli F, Rizzoli V, Meloni G.
    Haematologica; 1997 Jul; 82(3):291-6. PubMed ID: 9234574
    [Abstract] [Full Text] [Related]

  • 31. Cytokine treatment of human bone marrow activates anti-leukaemia effector cells: monitoring of purging by polymerase chain reaction and DNA analysis.
    Dickinson AM, Middleton SL, Latham J, Dunn J, Thomas L, Proctor SJ.
    Leukemia; 1995 Mar; 9(3):444-9. PubMed ID: 7533866
    [Abstract] [Full Text] [Related]

  • 32. Bone marrow-resident memory T cells survive pretransplant chemotherapy and contribute to early immune reconstitution of patients with acute myeloid leukemia given mafosfamide-purged autologous bone marrow transplantation.
    Casorati G, Locatelli F, Pagani S, Garavaglia C, Montini E, Lisini D, Turin I, Rossi F, Dellabona P, Maccario R, Montagna D.
    Exp Hematol; 2005 Feb; 33(2):212-8. PubMed ID: 15676215
    [Abstract] [Full Text] [Related]

  • 33. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM, Visani G, Leopardi G, Motta MR, Rizzi S, Testoni N, Curti A, Tura S.
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [Abstract] [Full Text] [Related]

  • 34. Antisense gene therapy trials underway in patients with CML.
    Oncology (Williston Park); 1996 Sep; 10(9):1411. PubMed ID: 8882929
    [No Abstract] [Full Text] [Related]

  • 35. Autologous transplantation for chronic myelogenous leukemia with mafosfamide-treated marrow.
    Rizzoli V, Mangoni L, Almici C, Caramatti C, Dotti GP, Carlo-Stella C.
    Stem Cells; 1993 Oct; 11 Suppl 3():25-30. PubMed ID: 8298474
    [Abstract] [Full Text] [Related]

  • 36. Bone marrow purging with antisense oligodeoxynucleotides.
    Gewirtz AM.
    Prog Clin Biol Res; 1992 Oct; 377():215-24; discussion 225-6. PubMed ID: 1438418
    [No Abstract] [Full Text] [Related]

  • 37. Bone marrow purging with oligodeoxynucleotides.
    Gewirtz AM, Luger SM, Stadtmauer E.
    Blood; 1996 Aug 15; 88(4):1517. PubMed ID: 8695876
    [No Abstract] [Full Text] [Related]

  • 38. Myeloablative treatment supported by autologous stem cell infusion with neuroblastoma.
    Ryu KH, Seoh JY, Jang PS, Kim CW, Koh SH, Shin HY, Ahn HS.
    J Korean Med Sci; 2003 Apr 15; 18(2):184-90. PubMed ID: 12692414
    [Abstract] [Full Text] [Related]

  • 39. [Autogeneic peripheral blood hemopoietic stem cell transplantation for chronic myeloid leukemia with imatinib mesylate-induced negative Philadelphia chromosome].
    Meng FY, Sun J, Liu QF, Xu D, Yang LJ, Song LL, Liu XL, Xu B, Zhou SY.
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Dec 15; 23(12):1301-2, 1306. PubMed ID: 14678896
    [Abstract] [Full Text] [Related]

  • 40. Ribozyme mediated therapy for chronic myelogenous leukemia.
    Leopold LH, Shore SK, Newkirk T, Mangan K, Reddy EP.
    Prog Clin Biol Res; 1994 Dec 15; 389():175-82. PubMed ID: 7700900
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.